List of Topics | WCAM 2027

01 Topics

Every session topic at WCAM 2027.

A complete, searchable index of session topics across 35 scientific sessions. Use this page to plan your attendance or to find the right call for your abstract submission.

01 Track

Opioid Use Disorder

Buprenorphine, methadone, naltrexone, fentanyl crisis.

Track details

Buprenorphine microinduction and high-dose strategies for fentanyl
Long-acting depot buprenorphine: Sublocade and Brixadi outcomes
Methadone access post-42 CFR Part 8 reform and pharmacy dispensing pilots
Extended-release naltrexone (Vivitrol): induction, retention, and reversal
Xylazine-adulterated supply: wound care, withdrawal, and detection
Lofexidine and adjunctive agents for opioid withdrawal
MOUD in pregnancy: buprenorphine vs methadone and NOWS management

02 Track

Alcohol Use Disorder

Behavioral therapies, naltrexone, acamprosate, AUDIT screening.

Track details

GLP-1 receptor agonists for AUD: semaglutide and tirzepatide trial data
Naltrexone (oral, extended-release) and the Sinclair method
Acamprosate, disulfiram, and supervised dosing models
Off-label pharmacotherapy: topiramate, gabapentin, baclofen evidence
AUDIT-C screening and SBIRT in primary care workflows
Alcohol-associated liver disease and early transplant referral
Managed alcohol programs and harm-reduction approaches to AUD

03 Track

Stimulants & Polysubstance Use

Cocaine, methamphetamine, contingency management.

Track details

Contingency management: VA implementation and Medicaid pilots
ADAPT-2: injectable naltrexone plus bupropion for methamphetamine
Topiramate, mirtazapine, and modafinil evidence in stimulant use
Polysubstance overdose: fentanyl-stimulant co-detection trends
Stimulant-induced cardiomyopathy and reversibility
Methamphetamine-associated psychosis and acute management
Cocaine vaccine and immunotherapy pipeline

04 Track

Behavioral Addictions

Gambling, gaming, internet — DSM frameworks and treatment.

Track details

Sports betting expansion and rising gambling disorder prevalence
DSM-5-TR gambling disorder and ICD-11 compulsive sexual behavior
Naltrexone and SSRIs in behavioral addiction pharmacotherapy
Internet gaming disorder: diagnostic criteria and treatment evidence
CBT, motivational interviewing, and 12-step in behavioral addictions
Neuroimaging convergence with substance use disorders
Screen-time interventions and family-based adolescent programs

05 Track

Harm Reduction

Naloxone, syringe services, overdose prevention sites.

Track details

OTC naloxone (Narcan, RiVive) and community distribution saturation
Overdose prevention centers: NYC and Rhode Island evaluation data
Fentanyl and xylazine test strips: legality and field utility
Drug checking with FTIR and mass spectrometry at music festivals
Safer supply pilots: British Columbia hydromorphone programs
Syringe services programs: HIV/HCV prevention and linkage to care
Post-overdose outreach teams and peer-led engagement models

06 Track

Medication-Assisted Treatment

Implementation science, low-threshold access, stigma.

Track details

ED-initiated buprenorphine and the CA Bridge model
Telehealth MOUD prescribing post-DEA flexibility extensions
Carceral MOUD: DOJ ADA enforcement and jail induction protocols
MAT Act implementation and post-X-waiver prescribing patterns
Office-based opioid treatment in primary care, HIV, and OB clinics
Provider stigma measurement and bias-reduction interventions
Bundled payment and value-based contracting for SUD treatment

07 Track

Recovery Support Services

Peer recovery coaches, recovery housing, employment.

Track details

Certified peer recovery specialists and Medicaid billing models
NARR-accredited recovery housing: Levels I-IV and MOUD inclusion
Oxford House and democratic recovery residence outcomes
Collegiate recovery programs and high school recovery academies
Recovery-friendly workplace certification and fair-chance hiring
Recovery community organizations and mutual-aid pluralism
Recovery capital measurement: BARC-10 and ARC scales

08 Track

Prevention & Early Intervention

School programs, SBIRT, family-based prevention.

Track details

LifeSkills Training and Strengthening Families: replication data
CRAFFT and S2BI screening in adolescent primary care
SBIRT implementation in pediatric and school-based clinics
Naloxone in schools and fentanyl awareness curricula
Communities That Care: coalition-driven prevention infrastructure
Youth vaping, nicotine pouch (Zyn), and cannabis vape prevention
Adverse childhood experiences (ACEs) and trauma-informed prevention

09 Track

Neuroscience of Addiction

Reward circuitry, craving, neurostimulation, biomarkers.

Track details

Deep brain stimulation of nucleus accumbens for refractory OUD/AUD
rTMS of dorsolateral prefrontal cortex for stimulant craving
Psilocybin-assisted therapy for AUD: Bogenschutz Phase 2/3 data
MDMA-assisted therapy for PTSD-SUD comorbidity
GLP-1 receptor signaling in mesolimbic reward circuitry
Real-time fMRI neurofeedback for craving regulation
Digital phenotyping and wearable biomarkers for relapse prediction

Have research aligned to one of these topics?

Submit your abstract by January 20, 2027. Oral and poster presentations are welcome across all nine tracks.

Submit Abstract